Welcome to our dedicated page for Tyra Biosciences SEC filings (Ticker: TYRA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Tyra Biosciences, Inc. (Nasdaq: TYRA) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Tyra Biosciences is a clinical-stage biotechnology company based in Carlsbad, California that focuses on developing precision medicines targeting FGFR biology through its in-house SNÅP platform. Its SEC filings give investors structured insight into how the company reports its financial condition, pipeline progress and material events related to its FGFR-focused programs.
Among the key documents, Form 8-K current reports are used by Tyra to announce material events such as quarterly financial results and significant clinical milestones. For example, recent 8-K filings reference press releases reporting second and third quarter financial results and an 8-K dated June 30, 2025 describing the first patient dosed in the SURF302 Phase 2 study of TYRA-300 (dabogratinib) in intermediate risk non-muscle invasive bladder cancer. These filings often incorporate press releases by reference, linking financial metrics with updates on studies like SURF302, BEACH301, SURF301, SURF201 and SURF431.
Investors can also use Tyra’s periodic reports (such as the annual report on Form 10-K and subsequent filings referenced in forward-looking statement sections) to understand risk factors, research and development priorities, and the status of clinical-stage candidates including dabogratinib, TYRA-200 and TYRA-430. The company’s filings discuss topics such as trial design, anticipated data readouts, dependence on third parties, regulatory interactions and intellectual property considerations.
On Stock Titan, these SEC filings are complemented by AI-powered summaries that help explain complex sections, highlight key disclosures and point out items of interest such as clinical trial milestones, cash runway commentary and forward-looking statements tied to the SNÅP platform and FGFR-targeted pipeline. Users can quickly review newly posted 8-Ks, 10-Ks and other forms, and connect them to Tyra’s broader narrative in precision oncology and genetically defined skeletal dysplasias.
Tyra Biosciences is a clinical-stage biotechnology company developing next‑generation precision small molecules focused on fibroblast growth factor receptor (FGFR) biology, using its in‑house SNÅP structure‑guided drug design platform.
The lead asset is oral dabogratinib (formerly TYRA‑300), an FGFR3‑selective inhibitor in three Phase 2 programs: SURF303 for low‑grade upper tract urothelial carcinoma, SURF302 for intermediate‑risk non‑muscle invasive bladder cancer, and BEACH301 for achondroplasia in children. The company plans potential registrational trials if Phase 2 data are successful and holds orphan drug and rare pediatric disease designations for achondroplasia.
Additional programs include TYRA‑430, an FGFR4/3‑biased inhibitor in a Phase 1 trial for FGF19‑positive hepatocellular carcinoma, and TYRA‑200, an FGFR1/2/3 inhibitor in Phase 1 for FGFR2‑driven intrahepatic cholangiocarcinoma resistant to prior FGFR therapy. Tyra reports a robust patent estate extending into the 2040s and relies on third‑party manufacturers while retaining global development and commercialization rights to all pipeline assets.
As of June 30, 2025, non‑affiliate common stock market value was approximately $297.3 million, and as of February 25, 2026, there were 53,867,115 shares outstanding.
Tyra Biosciences reported fourth-quarter and full-year 2025 results and outlined progress on its FGFR-focused pipeline. The company ended 2025 with $256.0 million in cash, cash equivalents and marketable securities and expects this to fund operations through at least 2027.
Research and development expenses rose to $28.2 million in Q4 and $102.9 million for 2025, driven mainly by oral dabogratinib clinical programs, including BEACH301 and SURF302 plus start-up for SURF303. General and administrative costs increased to $8.3 million in Q4 and $29.8 million for the year due to higher headcount-related spending.
Net loss was $33.8 million in Q4 and $119.9 million for 2025 as the company continues to invest in development. Tyra emphasized its “dabogratinib 3x3” strategy, concentrating on three Phase 2 studies in LG-UTUC, IR NMIBC and achondroplasia, with key data readouts expected in 2026.
Tyra Biosciences ownership disclosure: a group of Farallon funds and affiliated persons report shared dispositive power over certain blocks of Common Stock, including 2,984,818 shares (5.6%) held in the aggregate by multiple Farallon individual reporting persons. The filing lists additional holdings including 2,828,865 shares (5.3%) attributed to Farallon Partners, L.L.C., and 1,272,095 shares (2.4%) held by Farallon Capital Offshore Investors II, L.P.
The statement describes the reporting group structure, identifies the Farallon Funds and individual managing members, and notes that the reporting persons file under Section 13(d)-1(c).
Biotechnology Value Fund and related investment entities filed an amended Schedule 13G reporting their beneficial ownership of Tyra Biosciences, Inc. common stock. As of December 31, 2025, they may be deemed to beneficially own 2,127,665 shares, or approximately 4.0% of the outstanding shares, based on 53,372,098 shares outstanding as of October 31, 2025.
The holdings are spread across funds BVF, BVF2, and Biotechnology Value Trading Fund OS and a Partners-managed account, with complex control relationships among BVF GP, BVF2 GP, BVF GP Holdings, BVF Partners, BVF Inc., and Mark N. Lampert. Several entities expressly disclaim beneficial ownership of shares held by affiliated funds, and the group certifies that the securities are not held for the purpose of changing or influencing control of Tyra Biosciences.
Tyra Biosciences, Inc. Chief Discovery Officer Daniel Bensen reported planned stock sales. On February 12, 2026, he completed two open-market sales of Tyra Biosciences common stock under a pre-arranged Rule 10b5-1 trading plan adopted on November 5, 2024.
Bensen sold 2,128 shares at a weighted average price of $31.5018, with actual prices ranging from $31.02 to $31.75, and 5,872 shares at a weighted average price of $33.3666, with actual prices between $32.98 and $33.85. Following these transactions, he directly owned 146,981 shares of Tyra Biosciences common stock.
Todd Harris filed a Schedule 13G reporting his beneficial ownership of Tyra Biosciences, Inc. common stock. He reports beneficial ownership of 2,814,379 shares of common stock, representing 5.1% of the class, based on 53,706,357 shares outstanding as of December 31, 2025.
The holdings consist of 1,357,168 shares of common stock held directly and 1,457,211 shares underlying stock options that are currently exercisable or become exercisable within 60 days of December 31, 2025. Harris has sole voting and dispositive power over all 2,814,379 reported shares and no shared voting or dispositive power.
Tyra Biosciences, Inc. received an amended Schedule 13G from Canaan investment entities reporting beneficial ownership of its common stock. Canaan XI L.P. directly holds 2,930,444 shares, representing approximately 5.5% of the outstanding common stock, with Canaan Partners XI LLC deemed to beneficially own the same amount as its general partner.
Canaan 2020+ Co-Investment L.P. - Series 7 directly owns 443,885 shares, or about 0.8% of the outstanding shares, with Canaan Partners 2020+ Co-Investment LLC deemed to beneficially own the same. These percentages are based on 53,372,098 shares outstanding as of October 31, 2025. Each reporting person has sole voting and dispositive power over its reported shares.
Daniel Bensen filed a notice of proposed sale of 8,000 shares of TYRA common stock under Rule 144. The planned sale, through Merrill Lynch on the Nasdaq, has an indicated aggregate market value of $262,000, with 53,372,098 shares of the class shown as outstanding.
The shares to be sold were acquired as founders shares from the issuer on 08/28/2018. The filing also lists several recent sales of TYRA common stock by Bensen over the past three months, including transactions in November and December 2025 with gross proceeds up to $1,760,000.
Tyra Biosciences Chief Discovery Officer Bensen Daniel reported preset insider stock sales. On January 12, 2026, he sold 6,983 shares of Tyra Biosciences common stock at a weighted average price of $28.442 and an additional 1,017 shares at a weighted average price of $29.0808, both listed as open-market sales. These trades were carried out under a Rule 10b5-1 trading plan adopted on November 5, 2024, which is designed to pre-schedule transactions. After these sales, Daniel beneficially owned 154,981 shares of Tyra Biosciences common stock in direct ownership.
Tyra Biosciences shareholder Daniel Bensen has filed a Form 144 indicating an intent to sell additional common shares. The notice covers 8,000 shares of common stock to be sold through Merrill Lynch, with an approximate sale date of 01/12/2026 on Nasdaq. These 8,000 shares were acquired on 08/28/2018 as founder shares directly from the issuer.
The filing also lists recent sales by Bensen over the prior three months. Transactions include 1,111 shares on 11/13/2025 for gross proceeds of 17,000, 110,228 shares on 11/14/2025 for 1,760,000, 20,072 shares on 11/17/2025 for 320,000, 75,633 shares on 11/18/2025 for 1,200,000, 49,956 shares on 11/19/2025 for 815,000, and 8,000 shares on 12/12/2025 for 180,000. The form includes the standard representation that the seller is not aware of undisclosed material adverse information about the company.